Vanda Pharmaceuticals Receives FDA Approval for BYSANTI™
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy VNDA?
Source: PRnewswire
Vanda Pharmaceuticals' stock surged by nearly 40% in pre-market trading as it crossed above the 5-day SMA, following the FDA's approval of its new drug BYSANTI™ for treating bipolar I disorder and schizophrenia.
The FDA approval of BYSANTI™ (milsaperidone) as a first-line therapy marks a significant advancement in mental health treatment, expected to be commercially available in Q3 2026. This approval is anticipated to enhance Vanda's market position and attract investor interest, despite the broader market's decline, as analysts remain optimistic about the company's growth prospects.
The approval of BYSANTI™ not only expands Vanda's product portfolio but also opens new market opportunities, with analysts projecting a strong upside for the stock. The company's ongoing clinical trials and the drug's unique profile position Vanda for future growth in the mental health sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.680
Low
7.50
Averages
13.63
High
22.00
Current: 8.680
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these firms.
- EQIX Stock Outlook: Analysts' views on EQIX stock indicate a cautious market sentiment regarding its future performance, although specific ratings were not detailed in the report.
- Market Dynamics Overview: Changes in analyst ratings can significantly influence investor decisions, potentially leading to stock price volatility, prompting investors to closely monitor these developments.
- Access More Information: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing comprehensive market insights and investment references.
See More
FDA Grants Hearing for Vanda's Hetlioz Jet Lag Drug
- Hearing Approval: The FDA has granted a public hearing for Vanda Pharmaceuticals regarding its drug Hetlioz (tasimelteon) for jet lag, marking a rare occurrence for the agency and potentially the first in over four decades, indicating a significant scrutiny of the drug approval process.
- Rejection Reasons: In January, the FDA declined to approve the additional indication for Hetlioz, stating that the data submitted did not adequately demonstrate efficacy, which poses challenges for Vanda's market prospects.
- Current Approval Status: Hetlioz is currently approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome, showcasing its potential applications in specific areas.
- Market Reaction: Despite the FDA's approval of the hearing, Vanda's stock fell approximately 4% on Tuesday, reflecting market uncertainty regarding the future development of its drug.
See More
FDA Grants Vanda Hearing on Jet Lag Drug Rejection
- Hearing Approval: On March 2, 2026, the FDA approved Vanda's request for a formal hearing to review the proposed rejection of its supplemental new drug application for Hetlioz for jet lag treatment, marking the first such hearing in over 40 years, which could influence future approval processes.
- Clinical Trial Results: While the FDA acknowledged positive results from Vanda's recent clinical trials, it expressed concerns that the controlled phase-advance protocols used in the studies do not adequately replicate real-world flight conditions, potentially impacting the drug's practical application.
- Historical Rejection Background: Vanda's application for the jet lag indication was first rejected by the FDA in 2019, and a court-ordered re-review in August 2025 criticized the FDA for not adequately engaging with Vanda's evidence, highlighting the complexities and challenges in drug approvals.
- Market Reaction: Retail sentiment around VNDA stock on Stocktwits remained neutral over the past 24 hours, with message volume decreasing from high to low levels, although VNDA stock has gained 66% over the past 12 months, indicating cautious optimism in the market regarding the company's future prospects.
See More
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
- Hearing Approval: The FDA confirmed on March 2, 2026, that it will hold a formal evidentiary hearing to review Vanda's supplemental new drug application (sNDA) refusal for HETLIOZ®, a rare decision in over 40 years, highlighting the FDA's acknowledgment of the legal and scientific issues raised by Vanda.
- Legal Victory: Vanda successfully overturned the FDA's refusal of HETLIOZ® in August 2025, with the court ruling that the FDA inadequately considered Vanda's clinical trial evidence, emphasizing the company's seven-year effort for a fair review process, which could lead to greater transparency in future drug approvals.
- Market Potential: Currently approved for Non-24-Hour Sleep-Wake Disorder, if the sNDA is approved, HETLIOZ® would become the first FDA-approved treatment for jet lag disorder, addressing the needs of millions of travelers worldwide and presenting significant market expansion opportunities.
- Company Vision: Vanda is focused on developing innovative therapies to meet high unmet medical needs, and the progress of this hearing not only recognizes the company's efforts but may also propel its further development in the biopharmaceutical sector, enhancing its position in the industry.
See More
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
- Hearing Approval: The FDA confirmed on March 2, 2026, that it will hold a formal evidentiary hearing to review Vanda's supplemental new drug application (sNDA) refusal for HETLIOZ®, marking the first such hearing in over 40 years and highlighting the FDA's acknowledgment of Vanda's scientific evidence.
- Legal Victory: Vanda successfully challenged the FDA's refusal in August 2025, with the court ruling that the FDA inadequately considered Vanda's clinical trial data, mandating a re-evaluation of the sNDA, reflecting Vanda's commitment to advocating for scientific fairness.
- Market Potential: Currently approved for Non-24-Hour Sleep-Wake Disorder, HETLIOZ® could address a significant unmet need for millions of travelers suffering from jet lag if the sNDA is approved, indicating substantial market demand and commercial opportunity.
- Transparency Enhancement: This hearing represents not only a procedural victory for Vanda but also a significant reform in the FDA's drug approval process, potentially influencing future standards and procedures, thereby enhancing industry trust.
See More
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference
- Conference Participation: Vanda Pharmaceuticals announced its participation in the 2026 Citizens Life Sciences Conference in Miami on March 11, 2026, with a corporate presentation scheduled for 2:15 p.m. Eastern Time, highlighting its latest advancements in the biopharmaceutical sector.
- Online Access Convenience: Investors can access the conference presentation live on Vanda's corporate website, with a recommendation to register and download necessary software at least 15 minutes early, reflecting the company's commitment to investor communication.
- Post-Conference Availability: An archived link to the conference will be available for approximately 30 days after the event, aimed at providing information to investors who could not attend live, thereby enhancing transparency.
- Company Background: Vanda Pharmaceuticals is a leading global biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs and improve patient lives, showcasing its significant position in the industry.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these firms.
- EQIX Stock Outlook: Analysts' views on EQIX stock indicate a cautious market sentiment regarding its future performance, although specific ratings were not detailed in the report.
- Market Dynamics Overview: Changes in analyst ratings can significantly influence investor decisions, potentially leading to stock price volatility, prompting investors to closely monitor these developments.
- Access More Information: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing comprehensive market insights and investment references.
See More
FDA Grants Hearing for Vanda's Hetlioz Jet Lag Drug
- Hearing Approval: The FDA has granted a public hearing for Vanda Pharmaceuticals regarding its drug Hetlioz (tasimelteon) for jet lag, marking a rare occurrence for the agency and potentially the first in over four decades, indicating a significant scrutiny of the drug approval process.
- Rejection Reasons: In January, the FDA declined to approve the additional indication for Hetlioz, stating that the data submitted did not adequately demonstrate efficacy, which poses challenges for Vanda's market prospects.
- Current Approval Status: Hetlioz is currently approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome, showcasing its potential applications in specific areas.
- Market Reaction: Despite the FDA's approval of the hearing, Vanda's stock fell approximately 4% on Tuesday, reflecting market uncertainty regarding the future development of its drug.
See More
FDA Grants Vanda Hearing on Jet Lag Drug Rejection
- Hearing Approval: On March 2, 2026, the FDA approved Vanda's request for a formal hearing to review the proposed rejection of its supplemental new drug application for Hetlioz for jet lag treatment, marking the first such hearing in over 40 years, which could influence future approval processes.
- Clinical Trial Results: While the FDA acknowledged positive results from Vanda's recent clinical trials, it expressed concerns that the controlled phase-advance protocols used in the studies do not adequately replicate real-world flight conditions, potentially impacting the drug's practical application.
- Historical Rejection Background: Vanda's application for the jet lag indication was first rejected by the FDA in 2019, and a court-ordered re-review in August 2025 criticized the FDA for not adequately engaging with Vanda's evidence, highlighting the complexities and challenges in drug approvals.
- Market Reaction: Retail sentiment around VNDA stock on Stocktwits remained neutral over the past 24 hours, with message volume decreasing from high to low levels, although VNDA stock has gained 66% over the past 12 months, indicating cautious optimism in the market regarding the company's future prospects.
See More
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
- Hearing Approval: The FDA confirmed on March 2, 2026, that it will hold a formal evidentiary hearing to review Vanda's supplemental new drug application (sNDA) refusal for HETLIOZ®, a rare decision in over 40 years, highlighting the FDA's acknowledgment of the legal and scientific issues raised by Vanda.
- Legal Victory: Vanda successfully overturned the FDA's refusal of HETLIOZ® in August 2025, with the court ruling that the FDA inadequately considered Vanda's clinical trial evidence, emphasizing the company's seven-year effort for a fair review process, which could lead to greater transparency in future drug approvals.
- Market Potential: Currently approved for Non-24-Hour Sleep-Wake Disorder, if the sNDA is approved, HETLIOZ® would become the first FDA-approved treatment for jet lag disorder, addressing the needs of millions of travelers worldwide and presenting significant market expansion opportunities.
- Company Vision: Vanda is focused on developing innovative therapies to meet high unmet medical needs, and the progress of this hearing not only recognizes the company's efforts but may also propel its further development in the biopharmaceutical sector, enhancing its position in the industry.
See More
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
- Hearing Approval: The FDA confirmed on March 2, 2026, that it will hold a formal evidentiary hearing to review Vanda's supplemental new drug application (sNDA) refusal for HETLIOZ®, marking the first such hearing in over 40 years and highlighting the FDA's acknowledgment of Vanda's scientific evidence.
- Legal Victory: Vanda successfully challenged the FDA's refusal in August 2025, with the court ruling that the FDA inadequately considered Vanda's clinical trial data, mandating a re-evaluation of the sNDA, reflecting Vanda's commitment to advocating for scientific fairness.
- Market Potential: Currently approved for Non-24-Hour Sleep-Wake Disorder, HETLIOZ® could address a significant unmet need for millions of travelers suffering from jet lag if the sNDA is approved, indicating substantial market demand and commercial opportunity.
- Transparency Enhancement: This hearing represents not only a procedural victory for Vanda but also a significant reform in the FDA's drug approval process, potentially influencing future standards and procedures, thereby enhancing industry trust.
See More
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference
- Conference Participation: Vanda Pharmaceuticals announced its participation in the 2026 Citizens Life Sciences Conference in Miami on March 11, 2026, with a corporate presentation scheduled for 2:15 p.m. Eastern Time, highlighting its latest advancements in the biopharmaceutical sector.
- Online Access Convenience: Investors can access the conference presentation live on Vanda's corporate website, with a recommendation to register and download necessary software at least 15 minutes early, reflecting the company's commitment to investor communication.
- Post-Conference Availability: An archived link to the conference will be available for approximately 30 days after the event, aimed at providing information to investors who could not attend live, thereby enhancing transparency.
- Company Background: Vanda Pharmaceuticals is a leading global biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs and improve patient lives, showcasing its significant position in the industry.
See More
